

Clinical trials of hydralazine-ISDN

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
hydralazine-ISDN vs placebo			
VHeFT I (hydralazine ISDN) , 1986 n=186/273 follow-up: 2.3 y (range 0.5-5.7 years)	hydralazine 300mg/d ISDN 160mg/d versus placebo	patientst with chronic congestive heart failure and cardiac dilatation (CT ratio>0.55) or LVEF <45% in association with reduced exercise tolerance	Parallel groups double blind

More details and results :

- vasodilators therapy for heart failure in all type of patient at <http://www.trialresultscenter.org/go-Q79>

References

VHeFT I (hydralazine ISDN), 1986:

Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52 [[3520315](#)] [10.1056/NEJM198606123142404](https://doi.org/10.1056/NEJM198606123142404)